End-of-life Androgen Deprivation Syndrome With Enzalutamide in Metastatic Prostate Cancer: A Case Report.

IF 1.7 4区医学 Q4 ONCOLOGY

Anticancer research Pub Date : 2025-06-01 DOI:10.21873/anticanres.17625

Minh Dung Nguyen, Olena Gorobets, Yannick Joel Djoua, Johan Rose-Dite-Modestine, Vincent Vinh-Hung, Claire Verschraegen, Nam P Nguyen

{"title":"End-of-life Androgen Deprivation Syndrome With Enzalutamide in Metastatic Prostate Cancer: A Case Report.","authors":"Minh Dung Nguyen, Olena Gorobets, Yannick Joel Djoua, Johan Rose-Dite-Modestine, Vincent Vinh-Hung, Claire Verschraegen, Nam P Nguyen","doi":"10.21873/anticanres.17625","DOIUrl":null,"url":null,"abstract":"Background/aim: Enzalutamide is a highly effective anti-androgen for the treatment of prostate cancer. Therapy can incur unbearable fatigue in elderly patients, which might require a reduced dosage. However, the value of reduced-dose treatment to improve the long-term tolerability and to decrease the risk of toxicity remains unknown.Case report: We present the six-year clinical course of a patient treated upfront with low-dose enzalutamide (25% of the standard dose). Despite initial disease control and tolerance, the patient developed progressive frailty and signs of severe androgen deprivation near end-of-life.Conclusion: This case illustrates that while low-dose enzalutamide can provide durable disease control in elderly patients with metastatic castration-resistant prostate cancer, it does not fully prevent the late-onset toxicities associated with androgen deprivation. Personalized treatment strategies - including dose adjustment over time and consideration of intermittent therapy - may help to balance efficacy with quality of life.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 6","pages":"2535-2538"},"PeriodicalIF":1.7000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17625","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: Enzalutamide is a highly effective anti-androgen for the treatment of prostate cancer. Therapy can incur unbearable fatigue in elderly patients, which might require a reduced dosage. However, the value of reduced-dose treatment to improve the long-term tolerability and to decrease the risk of toxicity remains unknown.

Case report: We present the six-year clinical course of a patient treated upfront with low-dose enzalutamide (25% of the standard dose). Despite initial disease control and tolerance, the patient developed progressive frailty and signs of severe androgen deprivation near end-of-life.

Conclusion: This case illustrates that while low-dose enzalutamide can provide durable disease control in elderly patients with metastatic castration-resistant prostate cancer, it does not fully prevent the late-onset toxicities associated with androgen deprivation. Personalized treatment strategies - including dose adjustment over time and consideration of intermittent therapy - may help to balance efficacy with quality of life.

查看原文本刊更多论文

恩杂鲁胺治疗转移性前列腺癌终末期雄激素剥夺综合征1例报告。

背景/目的：恩杂鲁胺是一种治疗前列腺癌的高效抗雄激素。治疗可能会使老年患者产生难以忍受的疲劳，这可能需要减少剂量。然而，减少剂量治疗对提高长期耐受性和降低毒性风险的价值仍不清楚。病例报告：我们报告了一名患者6年的临床过程，该患者接受了低剂量的enzalutamide（标准剂量的25%）的前期治疗。尽管最初疾病得到控制和耐受，但患者在生命末期出现了进行性虚弱和严重雄激素剥夺的迹象。结论：本病例表明，虽然低剂量enzalutamide可以为老年转移性去势抵抗性前列腺癌患者提供持久的疾病控制，但它并不能完全预防与雄激素剥夺相关的晚发性毒性。个性化的治疗策略——包括随时间调整剂量和考虑间歇性治疗——可能有助于平衡疗效和生活质量。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Anticancer research 医学-肿瘤学

CiteScore

3.70

自引率

10.00%

发文量

566

审稿时长

2 months

期刊介绍： ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.